Article and Video CATEGORIES

Cancer Journey

Search By

Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University

Chief of Hematology/Oncology
Medical Director of Memorial Cancer Institute

Lung Cancer Video Library - Spanish Language: Video #22 Treating Stage III Unresectable NSCLC
Author
Luis Raez, MD FACP FCCP
 
 

Tratamiento para el cáncer de pulmón en estadio III no operable

En el caso de estadio IIIB no se pueden resecar, porque tienen un tumor que está invadiendo el mediastino y los grandes vasos. Normalmente ese tumor se podía sacar porque no hay metástasis, pero ya que la localización no es adecuada, no se puede sacar.

El tratamiento para un tumor en estadio IIIB cuando el tumor es inoperable, es dar quimioterapia con radioterapia al mismo tiempo. Como ustedes saben por un estudio famoso del grupo HOG, sabemos que el estándar es quimioterapia con cisplatino- etopósido y radiación, pero cisplatino-etopósido es una quimioterapia un poco antigua y tóxica. Por lo que hoy en día a pesar de que ese es el estándar de los grupos cooperativos americanos que usamos de referencia, preferimos dar carboplatino y paclitaxel, que es una quimioterapia fácil de manejar y que se da semanalmente.

Incluso en Estados Unidos, tenemos pacientes de edad mayor de 80-85 años que no van a tolerar el cisplatino ni etopósido, por eso el régimen de carboplatino-paclitaxel semanal es la quimioterapia de elección en estos estadios. Así que es muy importante tener estos criterios en cuenta cuando abordamos a los pacientes.


Treatment for lung cancer in stage III unresectable

In the case of stage III, is unresectable because they have a tumor invading the mediastinum or the great vessels. Usually this tumor would have been able to be resectable because it didn’t have metastasis, but the location is not adequate so that’s why it’s unresectable.

Treatment for a stage IIIB unresectable tumor is chemotherapy and radiotherapy at the same time. As you know, based in a famous trial by the group HOG, we know that the standard treatment is with cisplatin- etoposide and radiation, but cisplatin-etoposide is an old and toxic chemotherapy. So today, despite the standard American cooperative groups treatment, we prefer to use carboplatin and paclitaxel, which is a chemotherapy easy to handle and it’s given weekly.

Even in United States, we have elderly patients of 80-85 years old that will not tolerate cisplatin nor etoposide, so the weekly regimen of carboplatin- paclitaxel is the go therapy in these stages. So, it is very important to have these criteria when we are approaching the patients.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on